“益生菌1号”治疗肠易激综合征的临床疗效研究  

Study on the clinical efficacy of"probiotics No.1"in the treatment of irritable bowel syndrome

作　　者：刘宣 刘露路[1] 王珏[1] 郑艳[1] 曾懿[1] 古赛[1] LIU Xuan;LIU Lulu;WANG Jue;ZHENG Yan;ZENG Yi;GU Sai(Department of Gastroenterology,the First Affiliated Hospital of Chongqing Medical University,Chongqing 400016,China)

机构地区：[1]重庆医科大学附属第一医院消化内科,重庆400016

出　　处：《现代医药卫生》2021年第9期1449-1453,共5页Journal of Modern Medicine & Health

摘　　要：目的探讨“益生菌1号”治疗肠易激综合征(IBS)的疗效。方法选取2020年7-12月该院诊治的腹泻型IBS(IBS-D)及便秘型IBS(IBS-C)患者300例,随机分为试验组154例(IBS-C试验亚组40例,IBS-D试验亚组114例)与对照组146例(IBS-C对照亚组36例,IBS-D对照亚组110例),分别口服“益生菌1号”和安慰剂2周。于服药0、1、2周及停药1周评估各组患者IBS病情严重程度调查表(IBS-SSS)评分、布里斯托大便分类法(Bristol)分型评分,于服药0、2周评估各组患者IBS生活质量量表(IBS-QOL)评分,并记录服药期间不良反应发生情况。结果完成试验共264例,其中试验组134例(IBS-C试验亚组37例,IBS-D试验亚组97例),对照组130例(IBS-C对照亚组35例,IBS-D对照亚组95例)。试验、对照组及IBS-D试验亚组与IBS-D对照亚组患者服药1、2周后IBS-SSS评分,以及IBS-D试验、对照亚组患者服药1、2周后大便Bristol分型评分均较服药前明显降低,而试验组及IBS-D试验亚组下降程度较对照组及IBS-D对照亚组更明显,差异均有统计学意义(P<0.05)。IBS-C试验亚组患者IBS-SSS评分仅在服药2周后较服药前显著降低,差异有统计学意义(P<0.05)。试验组患者IBS-SSS评分应答率显著高于对照组,差异有统计学意义(P<0.05)。与服药2周时比较,对照组停药1周后IBS-SSS评分及IBS-D对照亚组大便Bristol分型评分显著回升,而IBS-C对照亚组此评分显著下降,差异均有统计学意义(P<0.05),而试验组及IBS-D、IBS-C试验亚组较之前无明显改变。服药2周后,试验、对照组及IBS-D试验、对照亚组患者IBS-QOL评分均较服药前显著降低,且试验组及IBS-D试验亚组下降程度较对照组及IBS-D对照亚组更明显,差异均有统计学意义(P<0.05)。IBS-C试验、对照亚组患者服药前后的IBS-QOL评分改变,差异均有统计学意义(P<0.05),未见其改变的组间差异。结论与安慰剂相比,服用“益生菌1号”2周可改善IBS患者总体症状、大便Objective To investigate the efficacy of"probiotics No.1"in the treatment of irritable bowel syndrome(IBS).Methods A total of 300 patients with diarrhea-type IBS(IBS-D)and constipation-type IBS(IBS-C)who were diagnosed and treated in the hospital from July to December 2020 were randomly divided into test group with 154 cases(IBS-C test subgroup 40 cases,IBS-D test subgroup 114 cases)and control group with 146 cases(IBS-C control subgroup 36 cases,IBS-D control subgroup 110 cases),respectively orally take"probiotics No.1"and placebo for 2 weeks.The IBS severity questionnaire(IBS-SSS)score and the Bristol classification(Bristol)classification score of the patients in each group were evaluated at 0,1,2 weeks of medication and 1 week of drug withdrawal.The IBS quality of life scale(IBS-QOL)score of each group was evaluated for 2 weeks,and the occurrence of adverse reactions during the medication was recorded.Results A total of 264 cases were completed,including 134 cases in the test group(37 cases in the IBS-C test subgroup,97 cases in the IBS-D test subgroup),130 cases in the control group(35 cases in the IBS-C control subgroup,and 95 cases in the IBS-D control subgroup).IBS-SSS scores of patients in the test group,control group,IBS-D test subgroup and IBS-D control subgroup at after 1 and 2 weeks of medication,and the stool Bristol scores of patients in the IBS-D test subgroup and control subgroup at after 1 and 2 weeks of medication were significantly lower than those before medication,and the decline in the test group and IBS-D test subgroup were more significant than those of the control group and IBS-D control subgroup,and the differences were statistically significant(P<0.05).The IBS-SSS scores of patients in the IBS-C test subgroup was only significantly lower after 2 weeks of medication than that before medication,and the difference was statistically significant(P<0.05).The response rate of IBS-SSS score in the test group was significantly higher than that in the control group,and the difference was statisti

关 键 词：肠易激综合征 益生菌 安慰剂 临床症状 大便性状 生活质量 

分 类 号：R714.255[医药卫生—妇产科学] R975[医药卫生—临床医学]